---
id: ada-diabetes-pharmacotherapy-2025
title: "ADA Standards of Care in Diabetes: Pharmacologic Approaches to Glycemic Treatment"
short_title: "ADA Diabetes Pharmacotherapy 2025"

organization: American Diabetes Association
collaborators: null
country: US
url: https://diabetesjournals.org/care/article/48/Supplement_1/S181/157569/
doi: 10.2337/dc25-S009
pmid: 39566271
open_access: true

specialty: endocrinology
guideline_type: clinical-practice
evidence_system: other
conditions:
  - type 2 diabetes
  - glycemic treatment
tags:
  - metformin
  - GLP-1 RA
  - SGLT2i
  - insulin

publication_date: 2025-01-01
previous_version_date: 2024-01-01
status: current
supersedes: ada-pharmacotherapy-2024
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-22
---

# ADA Standards of Care in Diabetes: Pharmacologic Approaches to Glycemic Treatment

## Scope
Evidence-based recommendations for pharmacologic treatment of type 2 diabetes, including medication selection, combination therapy, and management of cardiorenal comorbidities.

## Key Recommendations

### General Principles

#### Glycemic Targets
| Population | A1C Target |
|------------|------------|
| Most adults | <7% |
| High hypoglycemia risk/limited life expectancy | <8% |
| Motivated patients with low hypoglycemia risk | <6.5% |

#### Treatment Goals
- Glycemic management
- Weight management
- Cardiorenal protection
- Minimize hypoglycemia
- Person-centered approach

### First-Line Therapy

#### Metformin (Strong)
- First-line for most patients
- Start 500 mg daily or BID, titrate to 2000 mg/day
- Contraindicated: eGFR <30 mL/min
- Hold for contrast, surgery, acute illness

#### Early Combination Therapy
- Consider early combination if A1C ≥1.5% above target
- Do not delay pharmacotherapy at diagnosis

### Cardiorenal-Focused Selection

#### Patients with ASCVD or High CV Risk
**GLP-1 RA or SGLT2 inhibitor preferred (Strong)**

| Drug Class | Examples | Benefits |
|------------|----------|----------|
| GLP-1 RA | Semaglutide, liraglutide, dulaglutide | MACE reduction, weight loss |
| SGLT2i | Empagliflozin, canagliflozin, dapagliflozin | MACE reduction, HF benefit |

#### Patients with Heart Failure
**SGLT2 inhibitor recommended (Strong)**
- Reduces HF hospitalization
- Benefit independent of ejection fraction
- Use even if A1C at goal

#### Patients with CKD
**SGLT2 inhibitor + GLP-1 RA combination (Strong)**
- SGLT2i: Kidney protection down to eGFR 20-25
- Finerenone for additional nephroprotection (if albuminuria)
- GLP-1 RA: Additive kidney benefit

### GLP-1 Receptor Agonists

#### Available Agents
| Agent | Dosing | Notes |
|-------|--------|-------|
| Semaglutide (Ozempic) | 0.25→0.5→1→2 mg weekly | High efficacy |
| Tirzepatide (Mounjaro) | 2.5→5→10→15 mg weekly | GIP/GLP-1 dual agonist |
| Liraglutide | 0.6→1.2→1.8 mg daily | |
| Dulaglutide | 0.75→1.5→3→4.5 mg weekly | |
| Exenatide ER | 2 mg weekly | |

#### Side Effects
- Nausea (dose-related, improves over time)
- GI upset, constipation
- Injection site reactions
- Rare: Pancreatitis, gallbladder disease

### SGLT2 Inhibitors

#### Available Agents
| Agent | Dose | eGFR Considerations |
|-------|------|---------------------|
| Empagliflozin | 10-25 mg daily | Initiate if eGFR ≥20 |
| Dapagliflozin | 10 mg daily | Initiate if eGFR ≥25 |
| Canagliflozin | 100-300 mg daily | Initiate if eGFR ≥30 |

#### Side Effects
- Genital mycotic infections
- UTI (rare)
- Euglycemic DKA (rare)
- Volume depletion

### Other Glucose-Lowering Agents

#### DPP-4 Inhibitors
- Sitagliptin, linagliptin, saxagliptin, alogliptin
- Weight neutral
- CV safety (neutral)
- Do not combine with GLP-1 RA

#### Thiazolidinediones
- Pioglitazone: May have CV benefit
- Avoid in HF
- Weight gain, edema, fracture risk

#### Sulfonylureas
- Low cost
- Hypoglycemia risk
- Weight gain
- CV neutral

### Insulin Therapy

#### Indications
- Severe hyperglycemia (A1C >10%, symptomatic)
- Type 1 diabetes
- Pregnancy (if oral agents insufficient)
- Failure of non-insulin therapies

#### Initiation
| Insulin Type | Starting Dose | Titration |
|--------------|---------------|-----------|
| Basal insulin | 10 units or 0.1-0.2 U/kg | Increase 2-4 units every 3-7 days |
| GLP-1 RA + basal | Consider combination | Reduces insulin requirements |

### Weight Management

#### Prioritize Agents with Weight Loss
- GLP-1 RA (semaglutide, tirzepatide highest efficacy)
- SGLT2 inhibitors
- Avoid weight-gaining agents when possible

#### Weight Loss Medications
- May be indicated for BMI ≥27 with diabetes
- Continue beyond weight loss goals for maintenance

### Hypoglycemia Prevention
- Minimize use of insulin secretagogues and insulin when possible
- Patient education on recognition and treatment
- Continuous glucose monitoring consideration

### Monitoring
- A1C every 3-6 months
- Consider CGM for patients on multiple daily injections
- CGM may be useful for some patients on non-insulin therapy

